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Tables 1 and 5 in the above article have been published incorrectly. The correct tables are below. We
apologise for any inconvenience caused.
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Table 1 MICs (mg/L) of the P. aeruginosa clones with 38 different PFGE-patterns (¼38 isolates) and geometric mean values
(GM) at the beginning of the observation.
Table 5 Portion (%) of resistant, intermediate and sensitive P. aeruginosa clones with 22 different PFGE-patterns, number of isolates in brackets, in dependence of the
amount of inhaled gentamicin (g)
GEN AMK TOB
Amount of inhaled
gentamicin (g) sensitive intermediate resistant sensitive intermediate resistant sensitive intermediate resistant
5g (n¼ 22) 41% 59% 0% 59% 41% 0% 100% 0% 0%
10g (n¼ 10) 10% 70% 20% 10% 80% 10% 80% 20% 0%
15g (n¼ 13) 0% 84.6% 15.4% 7.7% 76.9% 15.4% 84.6% 7.7% 7.7%
20g (n¼ 16) 25% 43.8% 31.3% 25% 56.3% 18.8% 68.8% 18.8% 12.5%
25g (n¼ 18) 22.2% 50% 27.8% 33.3% 38.9% 27.8% 66.7% 22.2% 11.1%
>30g (n¼ 26) 19.2% 42.3% 38.5% 19.2 50% 30.8% 57.7% 42.3% 0%
GEN, Gentamicin; AMK, Amikacin; TOB, Tobramycin.
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